Your search matched 1 results
What Biogen’s Alzheimer’s Drug Approval Means for Life Sciences Companies | Blog
In a highly anticipated decision, the Food and Drug Administration (FDA) last week cleared Alzheimer’s disease drug aducanumab on an accelerated, conditional approval program.
© 2021 Syneos Health Communications, a Syneos Health company. All rights reserved.
Already have a RSS feed reader?